Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | TGM2 | P21980 | 5/20 | 0.50 |
| ▸ | F13A1 | P00488 | 4/20 | 0.50 |
| ▸ | TGM1 | P22735 | 4/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379160 | 0.90 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL7393652 | 0.90 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3970912 | 0.90 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL4814264 | 0.90 | MEN1 (0.76) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL15011579 | 0.89 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Bicarbonate SCHEMBL4357688 | 0.89 | MEN1 (0.73) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL1251533 | 0.87 | MEN1 (0.57) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL5534524 | 0.87 | MEN1 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL1251532 | 0.86 | MEN1 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 | |
| SCHEMBL3795583 | 0.85 | MEN1 (0.69) | MEN1KMT2ANPSR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592689-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-12-24 | — | — | EP | claimed |
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | claimed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | claimed |
| EP-1592689-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069162-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-08-19 | — | — | WO | claimed |
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2019038683-A1 | COMPOUNDS TARGETING TANDEM BRCT DOMAINS OF BRCA1, COMPOSITIONS AND METHODS THEREOF | INSTITUTE FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE (IN) | 2019-02-28 | — | — | WO | disclosed |
| US-9656978-B2 | Acylpiperazines as inhibitors of transglutaminase and their use in medicine | ASTON UNIVERSITY (GB) | 2017-05-23 | — | — | US | disclosed |
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | MEN1 4771/4885KMT2A 2548/4885NPSR1 3051/4885 |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | MEN1 910/4885KMT2A 1835/4885NPSR1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.